A US advisory panel on vaccines voted on Friday to end the long-standing recommendation that all newborns receive a hepatitis B vaccine at birth. Since 1991, the policy required the vaccination of all infants against the virus. The new recommendation advises that only babies born to mothers who have tested positive for hepatitis B should receive the shot immediately after birth.
The decision marks a significant shift in public health policy. The panel cited updated data on the low prevalence of hepatitis B in the general population and the effectiveness of prenatal screening. The change is expected to reduce unnecessary vaccinations and potential side effects in newborns.
Companies involved in vaccine development, such as Soligenix Inc. (NASDAQ: SNGX), may be affected by the policy change. Soligenix, which has vaccine programs in its pipeline, could see shifts in demand for its products. The full impact on the biotechnology sector remains to be seen.
The recommendation still requires approval from the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services before it becomes official. Until then, the current policy remains in effect.
This development highlights the evolving nature of vaccination guidelines based on current epidemiological data. The panel's vote reflects a move toward more targeted immunization strategies, focusing resources on high-risk populations.
For more information on the policy change and related news, visit BioMedWire, a platform covering the latest in biotechnology and life sciences.
